In8bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.981
- Today's High:
- $1.02
- Open Price:
- $1.0199
- 52W Low:
- $0.93
- 52W High:
- $3.95
- Prev. Close:
- $0.98
- Volume:
- 16712
Company Statistics
- Market Cap.:
- $32.55 million
- Book Value:
- 0.712
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -62.67%
- Return on Equity TTM:
- -125.86%
Company Profile
In8bio Inc had its IPO on 2021-07-30 under the ticker symbol INAB.
The company operates in the Healthcare sector and Biotechnology industry. In8bio Inc has a staff strength of 29 employees.
Stock update
Shares of In8bio Inc opened at $1.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.98 - $1.02, and closed at $0.98.
This is a +0.2% increase from the previous day's closing price.
A total volume of 16,712 shares were traded at the close of the day’s session.
In the last one week, shares of In8bio Inc have slipped by -7.36%.
In8bio Inc's Key Ratios
In8bio Inc has a market cap of $32.55 million, indicating a price to book ratio of 1.9559 and a price to sales ratio of 0.
In the last 12-months In8bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-29214000. The EBITDA ratio measures In8bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, In8bio Inc’s operating margin was 0% while its return on assets stood at -62.67% with a return of equity of -125.86%.
In Q2, In8bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
In8bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into In8bio Inc’s profitability.
In8bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3684. Its price to sales ratio in the trailing 12-months stood at 0.
In8bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $29.72 million
- Total Liabilities
- $3.78 million
- Operating Cash Flow
- $-22000.00
- Capital Expenditure
- $22000
- Dividend Payout Ratio
- 0%
In8bio Inc ended 2024 with $29.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $29.72 million while shareholder equity stood at $21.80 million.
In8bio Inc ended 2024 with $0 in deferred long-term liabilities, $3.78 million in other current liabilities, 4000.00 in common stock, $-76452000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.99 million and cash and short-term investments were $16.99 million. The company’s total short-term debt was $1,522,000 while long-term debt stood at $0.
In8bio Inc’s total current assets stands at $19.47 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $585000.00 and inventory worth $0.
In 2024, In8bio Inc's operating cash flow was $-22000.00 while its capital expenditure stood at $22000.
Comparatively, In8bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.98
- 52-Week High
- $3.95
- 52-Week Low
- $0.93
- Analyst Target Price
- $13
In8bio Inc stock is currently trading at $0.98 per share. It touched a 52-week high of $3.95 and a 52-week low of $3.95. Analysts tracking the stock have a 12-month average target price of $13.
Its 50-day moving average was $1.3 and 200-day moving average was $1.8 The short ratio stood at 0.26 indicating a short percent outstanding of 0%.
Around 2442.6% of the company’s stock are held by insiders while 3027.4% are held by institutions.
Frequently Asked Questions About In8bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.